Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • Sun Pharma's Halol unit: Observations are minor & could be remedied easily, says Nirmal Bang

    • Industry facing pricing & competition problems: Sun Pharma

    • Will continue to pursue inorganic growth in India & US: Torrent Pharma

    • Expect Rs 280-285 crore of topline in Sorbitol segment: Gulshan Polyols

    • Sun Pharma survives tax evasion charge on IPR transfer to foreign arm

    • No scope of US intervention in Indian pharma cos: Wockhardt

    • GST positive step for Indian industry, consumers: Dilip Shanghvi

    • ITI Reinsurance may kick off ops in October this year: Sources

    • Rollout of InfuSMART to begin with UK, Netherlands: Sun Pharma

    • Regulatory risks waning in pharma sector: IIFL

    • Lupin to see approvals after US FDA gives clean chit: Macquarie

    • Sun's psoriasis trial drug won't hit mkt before FY19: Analyst

    • Sun Pharma inks pact with ICGEB for dengue drug Cipa

    • Sun Pharma joins hands with ICMR for malaria eradication prog

    • Indian pharma cos need to step-up safeguards at plants: Handa

    • Pharma cos facing pricing pressure in US: PhillipCap

    • Elepsia drug more relevant to Sun Pharma: Phillipcap

    • Strides Arcolab to buy Aspen's generic biz in Australia

    • No plan to merge SPARC with Sun Pharma: Dilip Shanghvi

    • Sun Pharma to buy GSK's opiates business in Australia

    • Mineral-based projects will get sorted in 2 yrs: JSW Steel

    • Sun's margins may reduce to 30-32% post merger: Surajit Pal

    • Sun-Ranbaxy: Agency to monitor drug divestment, says CCI

    • Sun Pharma: Can the stock climb higher than all-time high?

      Sun Pharma was at lifetime high yesterday at Rs 854. It has received final approval for Novartis's Reclast/Aclasta, which is used in the treatment of osteoporosis.

    • Wyeth's claim on Protonix unjustified: Sun Pharma

      “We strongly believe that we have reasons to disagree with the claim that they have made. Fundamentally, we also believe that the patent invalidated is something that we will continue to fight for, Uday Baldota, vice president - investor relations, Sun Pharma told CNBC-TV18.

    Advisory Alert:

    It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347